You are viewing: United Kingdom Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The United Kingdom Recombinant Proteins Market was valued at $41.3 Million in 2023 and projected to reach to $62.8 Million by 2028, representing a compound annual growth rate of 8.7%. The United Kingdom recombinant proteins market is positioned for sustained growth, driven by increasing demand for targeted biologics, expanding therapeutic applications, and the country's established expertise in protein engineering.

United Kingdom Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

United Kingdom Recombinant Proteins Market Trends and Insights

  • This growth trajectory reflects the United Kingdom's strengthening position in biopharmaceutical innovation and therapeutic protein development.
  • The United Kingdom's advanced healthcare infrastructure, robust regulatory framework, and significant investment in biotechnology research are driving demand for recombinant protein therapeutics across multiple disease areas. The United Kingdom market is characterized by increasing adoption of recombinant proteins in oncology, immunology, and rare disease treatment.
  • The United Kingdom's pharmaceutical and biotech sectors are leveraging recombinant protein technology to develop novel therapeutics, supported by government initiatives and private sector collaboration.
  • Between 2023 and 2028, the United Kingdom is expected to see accelerated growth driven by rising healthcare expenditure, expanding clinical applications, and growing prevalence of chronic diseases requiring protein-based interventics..

Key Market Statistics

  • CAGR (2023-2028) 8.7% CAGR
  • Market Size, 2023 ~USD 41.3 Million
  • Forecast, 2028 ~USD 62.8 Million
  • Country United Kingdom

United Kingdom Recombinant Proteins Market Overview

Market Valuation Growth :

The UK recombinant proteins market reached $41.3 million in 2023 and is forecast to grow to $62.8 million by 2028, demonstrating robust expansion in the biopharmaceutical sector.

Strong CAGR Performance :

At 8.7% CAGR through 2028, the UK market is outpacing the global average of 7.2%, reflecting the country's competitive advantage in protein therapeutics development.

Regulatory Excellence :

The UK's advanced regulatory framework and post-Brexit autonomy enable faster approval pathways for recombinant protein therapeutics, attracting investment from global biopharmaceutical companies.

Research & Innovation Hub :

The UK hosts world-leading academic institutions and biotech clusters, particularly in Cambridge and London, driving innovation in recombinant protein manufacturing and therapeutic applications.

United Kingdom Recombinant Proteins Market Dynamics

  • The UK's life sciences sector benefits from significant government investment, collaborative research initiatives, and a skilled workforce specializing in biopharmaceutical development. Looking ahead to 2028, the market will be shaped by advances in manufacturing technologies, growing adoption of personalized medicine, and the UK's strategic focus on becoming a global life sciences leader.
  • Continued investment in biotech infrastructure and favorable regulatory conditions are expected to attract both domestic and international players, further accelerating market expansion and innovation in recombinant protein therapeutics..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The United Kingdom recombinant proteins market is valued at $41.3 million in 2023 and will reach $62.8 million by 2028, growing at 8.7% CAGR.
    • The United Kingdom's advanced regulatory environment and biotech infrastructure position it as a key hub for recombinant protein development and commercialization.
    • The United Kingdom market growth is driven by increasing adoption in oncology, immunology, and rare disease therapeutics.
    • The United Kingdom's healthcare system and government support for life sciences innovation are accelerating recombinant protein market expansion through 2028.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    United Kingdom Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    Target Audience

    • Biopharmaceutical Companies : UK and international pharma firms need detailed market data to assess expansion opportunities, optimize R&D investments, and develop targeted commercialization strategies for the UK recombinant proteins market.
    • Biotech Startups & SMEs : Emerging UK biotech companies require market intelligence to validate business models, secure funding, identify partnership opportunities, and position products within the competitive UK landscape.
    • Healthcare Investors & VCs : Investment firms evaluating UK life sciences opportunities need comprehensive market analysis to assess growth potential, identify promising companies, and make informed capital allocation decisions.
    • Contract Research Organizations : CROs and manufacturing partners need UK market forecasts to anticipate demand for services, plan capacity expansion, and develop service offerings aligned with market growth trajectories.
    • Healthcare Policy & Government Bodies : UK government agencies and NHS organizations require market data to inform life sciences strategy, allocate healthcare budgets, and support policy decisions affecting the recombinant proteins sector.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Obtain precise valuation data for the United Kingdom market ($41.3M in 2023) with detailed forecasts through 2028, enabling accurate budget allocation and investment planning for UK operations.
    • Competitive Landscape Intelligence : Understand the UK's unique competitive positioning with 8.7% CAGR outperforming global averages, identifying opportunities to capitalize on the country's regulatory advantages and innovation ecosystem.
    • Regulatory & Policy Insights : Gain clarity on UK-specific regulatory pathways, post-Brexit approval processes, and government support mechanisms that directly impact market entry strategies and commercialization timelines.
    • Investment & Partnership Opportunities : Identify high-growth segments and key stakeholders within the UK biotech cluster, including academic institutions, CROs, and manufacturers, to inform partnership and acquisition strategies.
    • Strategic Market Planning : Develop evidence-based go-to-market strategies tailored to the UK healthcare system, NHS procurement processes, and regional demand drivers for recombinant protein products.

    Frequently asked questions

    What is the current size of the United Kingdom recombinant proteins market?

    The United Kingdom recombinant proteins market was valued at $41.3 million in 2023 and is expected to grow to $62.8 million by 2028.

    What is the projected growth rate for the United Kingdom recombinant proteins market?

    The United Kingdom recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2028.

    Which therapeutic areas are driving growth in the United Kingdom recombinant proteins market?

    The United Kingdom market is experiencing strong growth in oncology, immunology, and rare disease treatment segments, supported by increasing clinical adoption and healthcare investment.

    What factors are supporting recombinant protein market expansion in the United Kingdom?

    The United Kingdom's advanced healthcare infrastructure, robust regulatory framework, government life sciences initiatives, and strong biotech sector are key drivers of market growth.

    How does the United Kingdom recombinant proteins market compare to other European markets?

    The United Kingdom's 8.7% CAGR reflects strong market fundamentals and positions the country as a significant player in European recombinant protein development and commercialization.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the recombinant proteins market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the recombinant proteins market. The secondary sources used for this study include The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Medical Association (AMA), Recombinant Antibody Network (RAN) National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Department of Agriculture (USDA), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), Institute for Molecular Medicine, Annual Reports, SEC Filings, Press Releases, Company Websites, Investor Presentations, Magazines, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global recombinant proteins market, which was validated through primary research.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the recombinant proteins market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The major players in the industry and market have been identified through extensive primary and secondary research.
    • The revenues generated from the recombinant proteins service business of players operating in the market have been determined through secondary research and primary analysis.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Global Recombinant proteins Market Size :Bottom-Up Approach

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Top-Down Approach

    Recombinant proteins Market Size, and Share

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    • Recombinant proteins are manipulated forms of proteins that are generated by recombinant DNA technology which modifies the gene sequences. These are formed by transfecting foreign genes into a host cell. They are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses.

    Key Stakeholders

    • Pharmaceutical and biotechnology companies
    • Life sciences companies
    • Academic research institutes
    • Government institutes
    • Private research firms
    • Contract Research Organizations (CROs)
    • Third-party suppliers, direct suppliers, distributors, and channel partners
    • Venture capitalists and investors
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market by product, application, host cell, end user, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa.
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships and research & development activities.
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

    Product Analysis

    • Product matrix, which provides a detailed comparison of the product portfolio of each company in the recombinant proteins Market

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status